Results

Merck & Co. Inc.

09/27/2021 | Press release | Distributed by Public on 09/27/2021 04:52

Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib